

# Pierre-Jean Lamy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5148169/publications.pdf>

Version: 2024-02-01

82  
papers

3,017  
citations

147566

31  
h-index

174990

52  
g-index

108  
all docs

108  
docs citations

108  
times ranked

5667  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. <i>Nature Medicine</i> , 2014, 20, 430-435.   | 15.2 | 582       |
| 2  | Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. <i>Translational Oncology</i> , 2013, 6, 319-IN8.   | 1.7  | 143       |
| 3  | HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer. <i>Cancer Treatment Reviews</i> , 2012, 38, 133-142.  | 3.4  | 109       |
| 4  | Identification of a New Panel of Serum Autoantibodies Associated with the Presence of <i>In situ</i> Carcinoma of the Breast in Younger Women. <i>Clinical Cancer Research</i> , 2009, 15, 4733-4741.                     | 3.2  | 99        |
| 5  | Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer. <i>Lung Cancer</i> , 2000, 29, 197-203.   | 0.9  | 88        |
| 6  | Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. <i>Lung Cancer</i> , 2003, 39, 131-138.  | 0.9  | 84        |
| 7  | Docetaxel and Cisplatin in Patients With Metastatic Androgen Independent Prostate Cancer and Circulating Neuroendocrine Markers. <i>Journal of Urology</i> , 2007, 178, 844-848.  | 0.2  | 81        |
| 8  | Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial. <i>Annals of Oncology</i> , 2015, 26, 908-914.      | 0.6  | 81        |
| 9  | Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021, 146, 30-47.   | 1.3  | 81        |
| 10 | Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes. <i>Scientific Reports</i> , 2018, 8, 15931.                            | 1.6  | 67        |
| 11 | Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review. <i>European Urology Focus</i> , 2018, 4, 790-803.   | 1.6  | 64        |
| 12 | Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. <i>Breast Cancer Research</i> , 2011, 13, R15.                  | 2.2  | 56        |
| 13 | KRAS Mutation Detection in Paired Frozen and Formalin-Fixed Paraffin-Embedded (FFPE) Colorectal Cancer Tissues. <i>International Journal of Molecular Sciences</i> , 2011, 12, 3191-3204.                                 | 1.8  | 52        |
| 14 | SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. <i>BMC Cancer</i> , 2013, 13, 351. | 1.1  | 52        |
| 15 | Identification of Pro-MMP-7 as a Serum Marker for Renal Cell Carcinoma by Use of Proteomic Analysis. <i>Clinical Chemistry</i> , 2008, 54, 574-581.   | 1.5  | 50        |
| 16 | Measles Virus Exploits Dendritic Cells to Suppress CD4+ T-Cell Proliferation via Expression of Surface Viral Glycoproteins Independently of T-Cell Trans-infection. <i>Cellular Immunology</i> , 2001, 214, 173-183.      | 1.4  | 49        |
| 17 | Progesterone Receptor Quantification as a Strong Prognostic Determinant in Postmenopausal Breast Cancer Women under Tamoxifen Therapy. <i>Breast Cancer Research and Treatment</i> , 2002, 76, 65-71.                     | 1.1  | 49        |
| 18 | Nonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk: results from the EPICAP study. <i>Cancer Medicine</i> , 2017, 6, 2461-2470.   | 1.3  | 48        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers. <i>British Journal of Cancer</i> , 2018, 119, 76-79.   | 2.9 | 48        |
| 20 | BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer. <i>BMC Cancer</i> , 2013, 13, 523.  | 1.1 | 44        |
| 21 | Iron homeostasis and anemia markers in early breast cancer. <i>Clinica Chimica Acta</i> , 2014, 434, 34-40.   | 0.5 | 42        |
| 22 | Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers. <i>International Journal of Cancer</i> , 2013, 132, 1105-1113.  | 2.3 | 41        |
| 23 | Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery. <i>Annales D'Endocrinologie</i> , 2017, 78, 162-175. | 0.6 | 39        |
| 24 | Night work and prostate cancer risk: results from the EPICAP Study. <i>Occupational and Environmental Medicine</i> , 2018, 75, 573-581.   | 1.3 | 39        |
| 25 | Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 709-717.  | 1.1 | 38        |
| 26 | Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles. <i>Breast Cancer Research</i> , 2011, 13, R133.  | 2.2 | 37        |
| 27 | Serum Autoantibody Signature of Ductal Carcinoma <i>In Situ</i> Progression to Invasive Breast Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1992-2000.   | 3.2 | 36        |
| 28 | The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2013, 1836, 146-157.  | 3.3 | 34        |
| 29 | Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 366-373.   | 1.2 | 34        |
| 30 | KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment. <i>Modern Pathology</i> , 2012, 25, 731-739.   | 2.9 | 33        |
| 31 | Abdominal obesity and prostate cancer risk: epidemiological evidence from the EPICAP study. <i>Oncotarget</i> , 2018, 9, 34485-34494.   | 0.8 | 33        |
| 32 | Serum HE4: An Independent Prognostic Factor in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2015, 10, e0128836.  | 1.1 | 28        |
| 33 | BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 828.  | 1.7 | 27        |
| 34 | Serum HER2 extra-cellular domain, S100 $\beta$ and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 428.   | 1.1 | 26        |
| 35 | Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study. <i>Annals of Oncology</i> , 2016, 27, 1235-1241.   | 0.6 | 25        |
| 36 | Serum protein signature may improve detection of ductal carcinoma in situ of the breast. <i>Oncogene</i> , 2010, 29, 550-560.   | 2.6 | 24        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Circulating Serum Vascular Endothelial Growth Factor is Not a Prognostic Factor of Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1119-1126.  | 0.5 | 23        |
| 38 | Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?. <i>International Journal of Cancer</i> , 2016, 139, 2299-2311. | 2.3 | 23        |
| 39 | NASBA: a novel approach to assess hormonal receptors and ERBB2 status in breast cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 3-12.   | 1.4 | 22        |
| 40 | Cathepsin D stimulates the activities of secreted plasminogen activators in the breast cancer acidic environment. <i>International Journal of Oncology</i> , 2013, 43, 1683-1690.   | 1.4 | 22        |
| 41 | Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study. <i>Cancers</i> , 2020, 12, 3002.   | 1.7 | 22        |
| 42 | Epidemiological study of prostate cancer (EPICAP): a population-based case-control study in France. <i>BMC Cancer</i> , 2014, 14, 106.  | 1.1 | 20        |
| 43 | Analysis of the potential contribution of estrogen receptor (ER) $\beta$ in ER cytosolic assay of breast cancer. <i>International Journal of Cancer</i> , 2001, 95, 205-208.  | 2.3 | 19        |
| 44 | Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2004, 91, 430-433.   | 2.9 | 19        |
| 45 | High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers. <i>BMC Cancer</i> , 2015, 15, 986.   | 1.1 | 19        |
| 46 | Body mass index trajectories and prostate cancer risk: Results from the EPICAP study. <i>Cancer Medicine</i> , 2020, 9, 6421-6429.  | 1.3 | 19        |
| 47 | PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 659-667.       | 1.1 | 17        |
| 48 | Circadian genes and risk of prostate cancer: Findings from the EPICAP study. <i>International Journal of Cancer</i> , 2019, 145, 1745-1753.   | 2.3 | 17        |
| 49 | Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor Type-1 mRNA Assessment in Breast Cancer by Means of NASBA. <i>American Journal of Clinical Pathology</i> , 2007, 128, 404-413.                               | 0.4 | 16        |
| 50 | Circadian genes polymorphisms, night work and prostate cancer risk: Findings from the EPICAP study. <i>International Journal of Cancer</i> , 2020, 147, 3119-3129.  | 2.3 | 16        |
| 51 | Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer. <i>Future Oncology</i> , 2014, 10, 195-209.   | 1.1 | 15        |
| 52 | Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?. <i>Future Oncology</i> , 2015, 11, 557-559.  | 1.1 | 15        |
| 53 | Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study. <i>BMC Cancer</i> , 2018, 18, 770.  | 1.1 | 15        |
| 54 | Androgenic hormones and the excess male mortality observed in COVID-19 patients: new convergent data. <i>World Journal of Urology</i> , 2021, 39, 3121-3123.  | 1.2 | 15        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Anemia and iron biomarkers in patients with early breast cancer. Diagnostic value of hepcidin and 1833-41.  | 1.4 | 14        |
| 56 | Worldwide variations in EGFR somatic mutations: a challenge for personalized medicine. Diagnostic Pathology, 2012, 7, 13.   | 0.9 | 13        |
| 57 | Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group. BMC Cancer, 2013, 13, 472.   | 1.1 | 11        |
| 58 | Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2âˆ’ pN0 early breast cancers. Breast Cancer Research and Treatment, 2017, 165, 611-621.   | 1.1 | 11        |
| 59 | <sc>P</sc>rostatitis, other genitourinary infections and prostate cancer risk: <sc>I</sc>nfluence of nonâ€steroidal antiâ€inflammatory drugs? <sc>R</sc>esults from the <sc>EPICAP</sc> study. International Journal of Cancer, 2018, 143, 1644-1651. | 2.3 | 11        |
| 60 | Clinical Utility of Serum Human Epidermal Growth Factor Receptor 2 Extracellular Domain Levels: Stop the Shilly-Shallyâ€”It Is Time for a Well-Designed, Large-Scale Prospective Study. Journal of Clinical Oncology, 2009, 27, e286-e287.            | 0.8 | 10        |
| 61 | Serum Matrix Metalloproteinaseâ€7 is an independent prognostic biomarker in advanced bladder cancer. Clinical and Translational Medicine, 2014, 3, 31.  | 1.7 | 10        |
| 62 | Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer. Clinical Breast Cancer, 2018, 18, 144-149.   | 1.1 | 10        |
| 63 | Family history of breast cancer increases the risk of prostate cancer: results from the EPICAP study. Oncotarget, 2018, 9, 23661-23669.   | 0.8 | 8         |
| 64 | KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?. British Journal of Cancer, 2010, 102, 1074-1075.   | 2.9 | 6         |
| 65 | High fasting serum insulin level due to autoantibody interference in insulin immunoassay discloses autoimmune insulin syndrome: a case report. Annales De Biologie Clinique, 2016, 74, 490-494.   | 0.2 | 4         |
| 66 | Occupation and prostate Cancer risk: results from the epidemiological study of prostate cancer (EPICAP). Journal of Occupational Medicine and Toxicology, 2022, 17, 5.  | 0.9 | 4         |
| 67 | Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group. European Journal of Cancer, Supplement, 2012, 10, 120-127.   | 2.2 | 3         |
| 68 | Added value of hepcidin quantification for the diagnosis and follow-up of anemia-related diseases. Annales De Biologie Clinique, 2017, 75, 9-18.  | 0.2 | 3         |
| 69 | First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma. Anticancer Research, 2018, 38, 2909-2914.   | 0.5 | 3         |
| 70 | Impact de la TEP/TDM au 18F-FDG dans la prise en charge des patients atteints de cancer thyroïdien diffÃ©renciÃ©. Medecine Nucleaire, 2010, 34, 78-87.  | 0.2 | 2         |
| 71 | <i>TOP2A</i> Amplification in Breast Cancer in the Absence of That of <i>HER-2</i>: Myth or Reality?. Oncologist, 2012, 17, e60-e61.  | 1.9 | 2         |
| 72 | Kinetics of HE4 and CA125 markers in metastatic ovarian cancer: The META4 study.. Journal of Clinical Oncology, 2017, 35, e17059-e17059.  | 0.8 | 2         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Classification moléculaire des cancers du sein: utilité en clinique. <i>Medecine Nucleaire</i> , 2010, 34, 32-43.   | 0.2 | 1         |
| 74 | Re: Clinical Validity/Utility, Change in Practice Patterns, and Economic Implications of Risk Stratifiers to Predict Outcomes for Early-Stage Breast Cancer: A Systematic Review. <i>Journal of the National Cancer Institute</i> , 2013, 105, 149-149. | 3.0 | 1         |
| 75 | Relevance of total PSA and free PSA prescriptions. <i>Annales De Biologie Clinique</i> , 2018, 76, 659-663.   | 0.2 | 1         |
| 76 | SERUM PRO-MATRIX METALLOPROTEINASE-7 (PRO-MMP-7) AS A PREDICTIVE MARKER FOR EARLY PROGRESSION AFTER NEPHRECTOMY IN RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2009, 181, 109-109.  | 0.2 | 0         |
| 77 | Cancer de la prostate: les niveaux de preuve des biomarqueurs de la détection précoce. <i>Medecine Nucleaire</i> , 2014, 38, 14-17.   | 0.2 | 0         |
| 78 | Quantification of uPA in breast tumour tissue extracts by microarray immunoassay: Comparison with ELISA technology. <i>Journal of Applied Biomedicine</i> , 2018, 16, 214-220.  | 0.6 | 0         |
| 79 | Abstract 679: Retrospective evaluation of the BRCA1 - PARP pathway in breast cancer tissues. , 2012, , .  |     | 0         |
| 80 | Comparison of prostate health index and PCA3 values in patients with clinical or biologic suspicion of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5055-5055.   | 0.8 | 0         |
| 81 | Abstract P5-21-02: Final results of the VitaCal randomized phase III study evaluating the impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients. , 2015, , .                  |     | 0         |
| 82 | Abstract P3-08-25: Simosein registry, the French national real-life prospective evaluation of the impact of Endopredict® (EPclin) on treatment decision in ER-positive, HER2-negative breast cancers. , 2020, , .                                       |     | 0         |